Abstract:Escherichia coli Nissle 1917 (EcN) is a probiotic bacterium, commonly employed to treat certain gastrointestinal disorders. It is fast emerging as an important target for the development of therapeutic engineered bacteria, benefiting from the wealth of knowledge of E. coli biology and ease of manipulation. Bacterial synthetic biology projects commonly utilize engineered plasmid vectors, which are simple to engineer and can reliably achieve high levels of protein expression. However, plasmids typically require antibiotics for maintenance, and the administration of an antibiotic is often incompatible with in vivo experimentation or treatment. EcN natively contains plasmids pMUT1 and pMUT2, which have no known function but are stable within the bacteria. Here, we describe the development of the pMUT plasmids into a robust platform for engineering EcN for in vivo experimentation, alongside a CRISPR-Cas9 system to remove the native plasmids. We systematically engineered both pMUT plasmids to contain selection markers, fluorescent markers, temperature sensitive expression, and curli secretion systems to export a customizable functional material into the extracellular space. We then demonstrate that the engineered plasmids were maintained in bacteria as the engineered bacteria pass through the mouse GI tract without selection, and that the secretion system remains functional, exporting functionalized curli proteins into the gut. Our plasmid system presents a platform for the rapid development of therapeutic EcN bacteria.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acssynbio.0c00466?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acssynbio.0c00466</a>.Table S1: DNA primers used in this work; Table S2: Sequence of UNS sequences; Table S3: gRNA sequences used in the pFREE and pCryptDel plasmids; Table S4: Variant TlpA* promoter sequences, and their properties; Figure S1: Detailed plasmid maps of pMUT1 and pMUT2; Figure S2: GFP and RFP characterization of engineered pMUT plasmids; Figure S3: Plasmid vectors to cure EcN cryptic plasmids; Figure S4: Curing native pMUT plasmids; Figure S5: In vivo synthetic plasmid loss; Supplementary methods for Figure S5; Figure S6: In vitro growth characterization of bacteria used in vivo (<a class="ext-link" href="/doi/suppl/10.1021/acssynbio.0c00466/suppl_file/sb0c00466_si_001.pdf">PDF</a>)Dataset S1: All data used in the figures (<a class="ext-link" href="/doi/suppl/10.1021/acssynbio.0c00466/suppl_file/sb0c00466_si_002.xlsx">XLSX</a>)Dataset S2: In vivo data (<a class="ext-link" href="/doi/suppl/10.1021/acssynbio.0c00466/suppl_file/sb0c00466_si_003.xlsx">XLSX</a>)This article has not yet been cited by other publications.

Genetic heterogeneity of engineered Escherichia coli Nissle 1917 strains during scale-up simulation

Mutator-driven Continuous Genome Evolution of Saccharomyces Cerevisiae

Engineering Escherichia coli Nissle 1917 as a microbial chassis for therapeutic and industrial applications

Plasmid Vectors for in Vivo Selection-Free Use with the Probiotic E. coli Nissle 1917

Synthetic extremophiles via species-specific formulations improve microbial therapeutics

Genome Dynamics of Escherichia coli during Antibiotic Treatment: Transfer, Loss, and Persistence of Genetic Elements In situ of the Infant Gut

Polymorphisms, Chromosomal Rearrangements, and Mutator Phenotype Development during Experimental Evolution of Lactobacillus rhamnosus GG

Overcoming genetic heterogeneity in industrial fermentations

Systems Metabolic Engineering to Elucidate and Enhance Intestinal Metabolic Activities of Escherichia coli Nissle 1917

Robust performance of a live bacterial therapeutic chassis lacking the colibactin gene cluster

Reduced evolvability of Escherichia coli MDS42, an IS-less cellular chassis for molecular and synthetic biology applications

Candidate probiotic Lactiplantibacillus plantarum HNU082 rapidly and convergently evolves within human, mice, and zebrafish gut but differentially influences the resident microbiome

Stabilized gene duplication enables long-term selection-free heterologous pathway expression

Establishment of the improved colonization of Escherichia coli laboratory strain in the intestine mediated by single gene deletion

Engineering E. coli strains using antibiotic-resistance-gene-free plasmids

Insights from metagenome-assembled genomes on the genetic stability and safety of over-the-counter probiotic products

Low mutational load and high mutation rate variation in gut commensal bacteria

Improving the growth and intestinal colonization of Escherichia coli Nissle 1917 by strengthening its oligopeptides importation ability

Improved cryptic plasmids in probiotic Escherichia coli Nissle 1917 for antibiotic-free pathway engineering

Development of a Genome-Scale Metabolic Model and Phenome Analysis of the Probiotic Escherichia coli Strain Nissle 1917

Development of potent in vivo mutagenesis plasmids with broad mutational spectra